Ongoing pharmaceutical reforms in France: Implications for key stakeholder groups

Keyphrases

• Stakeholder Groups 100%
• France 100%
• Rebates 100%
• New Drugs 100%
• Delisting 100%
• Generic Prescribing 100%
• Pharmaceutical Reform 100%
• Statins 50%
• Proton Pump Inhibitors 50%
• HMG-CoA Reductase Inhibitors 50%
• ACE Inhibitors 50%
• Angiotensin Receptor Blockers 50%
• Demand-side Measures 50%
• Physician Prescribing Patterns 50%
• Pharmaceutical Companies 50%
• Future Initiative 50%
• Limited Demand 50%
• Quality of Care 50%
• Innovative Drugs 50%
• Rapid Rise 50%
• Compartmentalization 50%
• Health Care Costs 50%
• Overall Cost 50%
• Chronic Disease Prevalence 50%
• Pharmaceutical Costs 50%
• Risk-benefit Ratio 50%
• Universal Coverage 50%
• Price-volume Agreement 50%
• Angiotensin II Type 1 Receptor Antagonist 50%
• Real-world Practice 50%
• Branded Products 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Antiinfective Agent 100%
• Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor 66%
• Chronic Disease 33%
• Prevalence 33%
• Proton Pump Inhibitor 33%
• Dipeptidyl Carboxypeptidase Inhibitor 33%
• Angiotensin Receptor Antagonist 33%
• Angiotensin 1 Receptor Antagonist 33%